These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8722543)

  • 41. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations.
    Kondo N; Ikawa K; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Ohge H; Morikawa N; Sueda T
    Pancreatology; 2014; 14(2):95-9. PubMed ID: 24650961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The pharmacokinetics of meropenem in surgical patients with moderate or severe infections.
    Lovering AM; Vickery CJ; Watkin DS; Leaper D; McMullin CM; White LO; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1995 Jul; 36(1):165-72. PubMed ID: 8537263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population Pharmacokinetics of Combined Intravenous and Local Intrathecal Administration of Meropenem in Aneurysm Patients with Suspected Intracranial Infections After Craniotomy.
    Li X; Sun S; Wang Q; Zhao Z
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):45-53. PubMed ID: 28616823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
    Maglio D; Teng R; Thyrum PT; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2003 May; 47(5):1771-3. PubMed ID: 12709358
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
    Krueger WA; Neeser G; Schuster H; Schroeder TH; Hoffmann E; Heininger A; Dieterich HJ; Forst H; Unertl KE
    Chemotherapy; 2003 Dec; 49(6):280-6. PubMed ID: 14671427
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis.
    Pettit RS; Neu N; Cies JJ; Lapin C; Muhlebach MS; Novak KJ; Nguyen ST; Saiman L; Nicolau DP; Kuti JL
    J Antimicrob Chemother; 2016 Jan; 71(1):189-95. PubMed ID: 26416780
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
    Usman M; Frey OR; Hempel G
    Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.
    Nehus EJ; Mizuno T; Cox S; Goldstein SL; Vinks AA
    J Clin Pharmacol; 2016 Mar; 56(3):291-7. PubMed ID: 26222329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
    Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
    Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of borneol on the concentration of meropenem in rat brain and blood.
    Xin HL; He XR; Li W; Zhou ZD; Zhang S; Wang GJ
    J Asian Nat Prod Res; 2014; 16(6):648-57. PubMed ID: 24827508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
    Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
    Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Application of HPLC to meropenem determination in plasma samples of patients with infections treated after coronary artery bypass graft surgery].
    Bafeltowska J; Pokorska A; Białek K; Wilczyński M
    Rocz Panstw Zakl Hig; 2010; 61(3):323-7. PubMed ID: 21365870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Meropenem clinical pharmacokinetics.
    Mouton JW; van den Anker JN
    Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
    Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
    Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
    Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
    J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics of high-dose extended-infusion meropenem during pulmonary exacerbation in adult cystic fibrosis patients: a case series.
    Delfino E; Fucile C; Del Bono V; Marchese A; Marini V; Coppo E; Casciaro R; Minicucci L; Giacobbe DR; Martelli A; Viscoli C; Mattioli F
    New Microbiol; 2018 Jan; 41(1):47-51. PubMed ID: 29313863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Meropenem: pharmacologic advantages of clinical interest].
    Domínguez-Gil Hurlé A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():32-7. PubMed ID: 9410067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Penetration of meropenem into human pancreatic juice.
    Ikawa K; Kondo N; Nakashima A; Yoshizawa K; Morikawa N; Ikeda K; Murakami Y; Ohge H; Sueda T
    Scand J Infect Dis; 2013 May; 45(5):404-6. PubMed ID: 23176150
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
    Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
    Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.